2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)Alexander R. Lyon, Julia Grapsa, Teresa López‐Fernández et al.|European Heart Journal|2022Cited by 2.7k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology SocietyAlexander R. Lyon, Daniel J. Lenihan, Teresa López‐Fernández et al.|European Journal of Heart Failure|2020Cited by 767
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)Alexander R. Lyon, Julia Grapsa, Teresa López‐Fernández et al.|European Heart Journal - Cardiovascular Imaging|2022Cited by 486
Role of Cardiovascular Imaging in Cancer Patients Receiving Cardiotoxic Therapies: A Position Statement on Behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)Jelena Čelutkienė, Alexander R Lyon, Radek Pudil et al.|European Journal of Heart Failure|2020Cited by 364
Role of Serum Biomarkers in Cancer Patients Receiving Cardiotoxic Cancer Therapies: A Position Statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of CardiologyRadek Pudil, Alexander R Lyon, Christian Mueller et al.|European Journal of Heart Failure|2020Cited by 344